



## Our 2022 Report

### **Janssen**

£130,000 went towards supporting the [Covid-19 Vaccine Research Collaborative](#). Another £37,000 went towards research undertaken by UCL in order to reduce [delays to diagnosis of blood cancer](#).

### **Gilead**

£300,000 went towards supporting the [Covid-19 Vaccine Research Collaborative](#).

### **Pfizer**

Pfizer gave £130,176 towards our emergency appeal to continue our support to people with blood cancer during the COVID-19 pandemic.

### **Novartis**

£80,000 went towards supporting our [Clinical Trials Support Service](#). We also received £15,000 from Novartis which was redirected to the Blood Cancer Alliance for their membership.

### **Takeda**

£100,000 went towards supporting the [Covid-19 Vaccine Research Collaborative](#). Another £60,000 went towards supporting our [Clinical Trials Support Service](#).

### **Bristol Myers Squibb**

£230,000 went towards supporting the [Covid-19 Vaccine Research Collaborative](#). Another £60,000 went towards supporting our [Clinical Trials Support Service](#).

### **AbbVie**

AbbVie gave £12,000 for our befriending service.

### **Roche**

£100,000 went towards supporting the Covid-19 Vaccine Research Collaborative.



### **Jazz**

Jazz gave £10,000 to support our health information project and £10,000 towards a project supporting marginalised communities.

### **Incyte**

Incyte gave £15,000 to support our health information project.

### **AstraZeneca**

AstraZeneca paid Blood Cancer UK £308 for our participation in an advisory board.

### **Kyowa Kirin**

£5,000 went towards a project supporting marginalised communities.

### **Autolus**

Autolus gave £75,000 to support our [Clinical Trials Support Service](#).

### **GSK**

£10,000 went towards a project supporting marginalised communities.

### **UCB Pharma**

£1,000 went towards our support services.